Latest news with #Qure.ai
&w=3840&q=100)
Business Standard
5 days ago
- Business
- Business Standard
Quadria Group announces HealthQuad Fund III with $300 million corpus
Private equity firm Quadria Group on Tuesday announced the launch of HealthQuad Fund III, with a target corpus of $200 million and a $100 million in greenshoe option. HealthQuad Fund III succeeds Funds I and II, which have supported over 18 healthcare companies, including Medikabazaar, THB, Wysa, Ekincare, Redcliffe Labs, GoApptiv, and Strand Life Sciences. Quadria Group is aiming to raise $300 million (about Rs 2,550 crore) for its HealthQuad Fund III. Quadria Group has retained a large part of the existing investment and investment committee team members, who will continue to be involved in the existing portfolio investments, a company statement said. It will also add more people to its investing, operating and clinical team. "India presents one of the world's most compelling healthcare investment opportunities, driven by growing demand, digital acceleration, and underserved segments across primary, diagnostic, and chronic care. "With the full ownership of Fund III and expanded leadership, we are better positioned than ever to deliver cross-regional value for our portfolio companies, across South Asia, Southeast Asia, and the GCC, creating an unparalleled platform for health innovation," Amit Varma, co-founder and Investment Committee member, HealthQuad, said. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Time of India
5 days ago
- Business
- Time of India
Quadria Group launches third HealthQuad fund with a corpus of $300 million
MUMBAI: Quadria Group, a healthcare-focused private equity platform on Tuesday announced the launch of HealthQuad Fund III, with a proposed raise of up to $300 million. The fund seeks to back healthcare ventures that have significantly expanded access, affordability, and quality of care across India. Funds I and II backed over 18 companies including Medikabazaar, THB, Wysa, Ekincare, Redcliffe Labs, GoApptiv, and Strand Life Sciences. Dr. Amit Varma, Co-founder and Investment Committee member, HealthQuad, said, 'India presents one of the world's most compelling healthcare investment opportunities—driven by growing demand, digital acceleration, and underserved segments across primary, diagnostic, and chronic care. With the full ownership of Fund III and expanded leadership, we are better positioned than ever to deliver cross-regional value for our portfolio companies, across South Asia, Southeast Asia, and the GCC, creating an unparalleled platform for health innovation. ' Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Time of India
23-05-2025
- Health
- Time of India
Qure.ai launches AI tool to aid health workers in LMICs
Mumbai: AI solution provider company has introduced AIRA, an AI-powered co-pilot tool for frontline healthcare workers in low- and middle-income countries (LMICs) at the 78th World Health Assembly in Geneva this week. The company states that community health workers spend over 40 per cent of their time on manual data collection, yet many countries still lack sufficient population-level data for decision-making. According to the company, AIRA is designed to ease the burden on healthcare workers by automating symptom and patient history collection, supporting adherence to clinical protocols, and generating population-level health insights . It aims to address key challenges in LMICs, including a projected shortage of 11 million health workers by 2030 and the 17 million preventable deaths that occur annually. 'With AI, we can multiply every dollar spent and realize significantly more impact and returns in LMIC health systems,' said Prashant Warier, CEO and Founder,
The Print
10-05-2025
- Health
- The Print
Johnson & Johnson Medtech Partners with Qure.ai to Boost Early Detection of Lung Cancer in India
Mumbai (Maharashtra) [India], May 9: Johnson & Johnson MedTech, a global leader in surgical technologies and solutions, has onboarded a global leader in artificial intelligence (AI) for healthcare, as a strategic partner with Johnson & Johnson Private Limited, a Johnson & Johnson company, to enhance early detection of lung cancer in India. This collaboration brings together cutting-edge AI and medical technology, helping identify lung cancer at its most treatable stage. This initiative is part of Project BreatheEZ, a broader strategic collaboration between and Johnson & Johnson MedTech, and designed to establish AI-led Incidental Pulmonary Nodule (IPN) Detection clinics across leading hospitals in India. These clinics will act as integrated screening hubs, optimizing early detection, triaging, and follow-up care for lung cancer patients. As part of this collaboration, AI technology will be deployed across 10 hub medical centers in India, with an additional 20 supporting spoke sites. The first such clinic has been launched in Thangam Cancer Centre in Namakkal, Tamil Nadu. In India, one in nine persons is likely to be diagnosed with cancer in their lifetime. It is an increasing health concern, and the projected cancer burden is expected to rise from 26.7 million DALYs (Disability-Adjusted Life Years) in 2021 to 29.8 million in 2025¹. This growing health challenge needs innovative solutions to improve early detection and ultimately save lives. Traditional diagnostic methods often fail to detect lung cancer at an early stage, leading to delays in treatment. Thus, this collaboration between Johnson & Johnson MedTech and marks a significant leap forward. By harnessing of artificial intelligence in the modalities of X-Ray & CT scans, Johnson & Johnson MedTech India & are enabling the detection of potential lung nodules that might otherwise be missed. This happens through flagging risky nodules in X-Rays and CT Scans that can potentially turn out to be malignant. It also introduces the concept of structured IPN clinics where there is a proactive impetus towards incidental screening of early-stage lung cancer. This partnership embodies Johnson & Johnson MedTech's commitment to enhancing early lung cancer detection, ultimately transforming the standard of lung cancer care. Anuj Virmani, Managing Director, India, Johnson & Johnson MedTech, said, 'Lung cancer continues to be one of the leading causes of cancer in both men and women. In India, where access to advanced healthcare facilities is often limited, especially in tier-2 and tier-3 cities, patients face significant challenges in receiving timely and effective diagnosis, which further delays access to treatment. Our collaboration with is a testament to our commitment to advancing healthcare through innovative solutions continues to drive impactful collaborations and integrating our solutions in lung cancer.' Reference: 1. ICMR and NCDIR World Cancer Day 2024, Close the care gap- Addressing cancer care in India, 04th – February – 2024 Surgical Solutions from Johnson & Johnson MedTech Across Johnson & Johnson, we are tackling the world's most complex and pervasive health challenges. For over 100 years, we have helped advance surgical care through our innovative portfolio across wound closure, adjunctive hemostats, surgical stapling and instruments, robotics and digital solutions. Together, with clinicians and healthcare experts around the world we are progressing what's next in surgery to better solve patient needs in metabolic and cardiovascular disease, cancer, and aesthetics and reconstruction. For more, visit (ADVERTORIAL DISCLAIMER: The above press release has been provided by BusinessWire India. ANI will not be responsible in any way for the content of the same) This story is auto-generated from a syndicated feed. ThePrint holds no responsibility for its content.
Time of India
08-05-2025
- Health
- Time of India
J&J Medtech, Qure.ai partner to boost early detection of lung cancer in India
Mumbai: Johnson & Johnson MedTech announced its collaboration with as a strategic partner with Johnson & Johnson Private Limited, to enhance early detection of lung cancer in India to bring together cutting-edge AI and medical technology which will help identify lung cancer at its most treatable stage. This initiative is part of Project BreatheEZ , a broader strategic collaboration between and Johnson & Johnson MedTech, and designed to establish AI-led Incidental Pulmonary Nodule (IPN) Detection clinics across leading hospitals in India. These clinics will act as integrated screening hubs, optimizing early detection, triaging, and follow-up care for lung cancer patients. As part of this collaboration, AI technology will be deployed across 10 hub medical centers in India, with an additional 20 supporting spoke sites. The first such clinic has been launched in Thangam Cancer Centre in Namakkal, Tamil Nadu, stated the press release. In India, one in nine persons is likely to be diagnosed with cancer in their lifetime. It is an increasing health concern, and the projected cancer burden is expected to rise from 26.7 million DALYs (Disability-Adjusted Life Years) in 2021 to 29.8 million in 20251. This growing health challenge needs innovative solutions to improve early detection and ultimately save lives. Anuj Virmani, Managing Director, India, Johnson & Johnson MedTech, said, 'Our collaboration with is a testament to our commitment to advancing healthcare through innovative solutions continues to drive impactful collaborations and integrating our solutions in lung cancer.'
